SUBCUTANEOUS BIOLOGICS MARKET ANALYSIS

Market News

Key Developments

1. Key players in the market are involved in various business strategies such as gaining biologics license from regulatory authorities. For instance, in July 2018, Halozyme Therapeutics, Inc. announced that the U.S. Food and Drugs Administration (FDA) accepted biologics license from ‘Genentech’, a member of the Roche Group, for subcutaneous formulation of trastuzumab (Herceptin), which is company’s FDA approved indication for breast cancer.
2. Major players in the market are focused on gaining approvals for products and treatment from regulatory authorities, in order to gain competitive edge in the market. For instance, in October 2018, Roche AG received the U.S. Food and Drugs Administration approval for Hemlibra, which is a routine treatment for adults and children suffering from bleeding episode. It consists haemophilia A without factor VIII inhibitors, which will reduce the frequency of bleeding episodes.
3. Major players in the market are focused on gaining approvals for products and treatment from regulatory authorities, in order to gain competitive edge in the market. For instance, in September 2018, AstraZenca and Amgen received the U.S. Food and Drug Administration ‘Breakthrough Therapy Designation’ for tezepelumab, which will be used for patients with severe asthma without an eosinophilic phenotype.